Activity Overview

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies. Pathologists face challenges due to heterogeneous morphology, complex biopsy samples, and evolving World Health Organization (WHO) classifications that complicate accurate diagnosis and risk stratification. Clinicians and pathologists often encounter persistent gaps in distinguishing neuroendocrine tumors (NETs) from NECs, incorporating RB/p53 and Ki-67 into grading and risk stratification and leveraging emerging biomarkers such as DLL3 and molecular profiling to inform prognosis, guide eligibility for biomarker-driven trials, and anticipate potential targeted therapies.

This CME-certified hybrid symposium features an expert panel of pathologists and medical oncologists using a Medical Crossfire^® format to dissect real-world diagnostic dilemmas in EP-NECs, including grading pitfalls, mixed/amphicrine tumors, and differences between pulmonary and extrapulmonary disease. Through guideline- and WHO-focused discussions, case-based debate, and integration of contemporary immunohistochemistry and next-generation sequencing data, participants will learn to apply current diagnostic criteria, key biomarker panels, and emerging therapeutic markers to improve the classification and management of patients with high-grade neuroendocrine neoplasms.

This educational activity is an archive of the live virtual symposium held on March 24, 2026.

Target Audience

This educational activity is directed toward pathologists, as well as oncologists, advanced practice providers, oncology nurses, and other health care professionals involved in the multidisciplinary care of patients with EP-NECs.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Apply current guideline-recommended criteria and diagnostic methods to accurately distinguish NECs from NETs
Evaluate the emerging role of biomarkers, including DLL3, in the pathogenesis, diagnosis, prognosis, and treatment of EP-NECs
Integrate molecular profiling and next-generation sequencing into pathology

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

GET STARTED WITH THIS PROGRAM:

Related Content